Dr Lalchandani Labs Ltd Stock Price Today (NSE: DLCL)
Fundamental Score
Dr Lalchandani Labs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Dr Lalchandani Labs Ltd share price today is ₹14.81, up +0.00% on NSE/BSE as of 30 March 2026. Dr Lalchandani Labs Ltd (DLCL) is a Small-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹8.77 (Cr). The 52-week high for DLCL share price is ₹28.70 and the 52-week low is ₹9.80. At a P/E ratio of 18.66x, DLCL is currently trading below its industry average P/E of 39.28x. The company has a Return on Equity (ROE) of 3.08% and a debt-to-equity ratio of 0.45.
Dr Lalchandani Labs Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Dr Lalchandani Labs Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Dr Lalchandani Labs Share Price: A Financial Analysis for Industry Dominance
The healthcare service provider landscape is undergoing rapid consolidation, rewarding companies with robust operational efficiency and geographic reach. This analysis delves into the financial standing of Dr Lalchandani Labs Ltd, focusing on its potential for industry dominance. Currently, the Dr Lalchandani Labs share price sits at ₹16.71, with a Price-to-Earnings (PE) ratio of 18.66. A key factor to consider is its Return on Capital Employed (ROCE) of 2.81%.
While a PE of 18.66 might seem reasonable in isolation, it needs to be contextualized within the sector. How does it stack up against peers like Suraksha Diagnostic Ltd or Aspira Pathlab & Diagnostics Limited? While we cannot definitively assess relative management quality without deeper access, one observation is that
Suraksha Diagnostic Ltd appear to be commanding higher valuations potentially due to perceived stronger market positioning or operational efficiencies. A detailed comparison of key management metrics like cost-to-income ratios would be insightful in this domain.The 2.81% ROCE raises concerns about Dr Lalchandani Labs' ability to build a sustainable competitive advantage, or moat. ROCE reflects how effectively the company is generating profits from its invested capital. A low ROCE suggests either inefficient asset utilization or weak profitability on its operations. This directly impacts the company's capacity to reinvest earnings for future growth, expand its service offerings, or fend off competition. While other healthcare service providers are improving ROCE to 15-20%, Dr Lalchandani Labs Ltd needs to target that range to attract significant investment.
It is important to note that this financial analysis is part of a more extensive 80-parameter fundamental audit process, verified by Sweta Mishra. This analysis is purely observational and should not be considered investment advice. Any investment decision should be based on thorough research and consultation with a qualified financial advisor.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Dr Lalchandani Labs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of DLCL across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Operating Margins (16.83%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 18.66 vs Industry: 39.28)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (33.33%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Interest Coverage (12.50x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (3.08%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (2.81%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Limited Growth History (-6.11% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-8.59% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-8.59% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Dr Lalchandani Labs Ltd Financial Statements
Comprehensive financial data for Dr Lalchandani Labs Ltd including income statement, balance sheet and cash flow
About DLCL (Dr Lalchandani Labs Ltd)
Dr Lalchandani Labs Ltd is a renowned healthcare service provider at the forefront of diagnostics and preventative health in India. With a legacy built on accuracy and patient-cent...ric care, DLCL offers a comprehensive suite of services designed to cater to diverse healthcare needs. The labs function as critical hubs for precision medicine, delivering high-quality pathology testing alongside cutting-edge imaging modalities. DLCL empowers patients and medical professionals with vital information to facilitate timely diagnoses, informed treatment decisions, and proactive wellness management. The company remains steadfast in its mission to elevate the standards of diagnostic care across the country. DLCL distinguishes itself through its integrated approach to healthcare, providing a seamless experience for patients and partners alike. Beyond routine testing, DLCL offers a range of specialized services, including advanced molecular diagnostics, comprehensive health check packages, and expert consultations. Strategic partnerships with hospitals and corporations further extend DLCL's reach, enabling the delivery of on-site lab management and customized health solutions. Through a combination of skilled professionals, state-of-the-art technology, and unwavering commitment to quality, DLCL continuously strives to meet the evolving demands of the Indian healthcare landscape. Embracing innovation and accessibility, Dr Lalchandani Labs Ltd extends its services beyond traditional brick-and-mortar locations. Their robust online platform offers convenient access to test bookings, report delivery, and personalized health insights. By leveraging technology, DLCL aims to democratize healthcare and empower individuals to take control of their well-being. With a focus on continuous improvement and a deep understanding of the unique needs of the Indian population, Dr Lalchandani Labs Ltd stands as a trusted partner in promoting health and well-being across communities.
Company Details
Key Leadership
Latest News
DLCL Share Price: Frequently Asked Questions
What is the current share price of Dr Lalchandani Labs Ltd (DLCL)?
As of 30 Mar 2026, 11:00 am IST, Dr Lalchandani Labs Ltd share price is ₹14.81. The DLCL stock has a market capitalisation of ₹8.77 (Cr) on NSE/BSE.
Is DLCL share price Overvalued or Undervalued?
DLCL share price is currently trading at a P/E ratio of 18.66x, compared to the industry average of 39.28x. Based on this relative valuation, the Dr Lalchandani Labs Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of DLCL share price?
The 52-week high of DLCL share price is ₹28.70 and the 52-week low is ₹9.80. These values are updated daily from NSE/BSE price data.
What factors affect the Dr Lalchandani Labs Ltd share price?
Key factors influencing DLCL share price include quarterly earnings growth (Sales Growth: -3.76%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Dr Lalchandani Labs Ltd a good stock for long-term investment?
Dr Lalchandani Labs Ltd shows a 5-year Profit Growth of -8.59% and an ROE of 3.08%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.45 before investing in DLCL shares.
How does Dr Lalchandani Labs Ltd compare with its industry peers?
Dr Lalchandani Labs Ltd competes with major peers in the Healthcare Service Provider. Investors should compare DLCL share price P/E of 18.66x and ROE of 3.08% against the industry averages to determine competitive standing.
What is the P/E ratio of DLCL and what does it mean?
DLCL share price has a P/E ratio of 18.66x compared to the industry average of 39.28x. Investors pay ₹19 for every ₹1 of annual earnings.
How is DLCL performing according to Bull Run's analysis?
DLCL has a Bull Run fundamental score of 4.4/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does DLCL belong to?
DLCL operates in the Healthcare Service Provider industry. This classification helps understand the competitive landscape and sector-specific trends affecting Dr Lalchandani Labs Ltd share price.
What is Return on Equity (ROE) and why is it important for DLCL?
DLCL has an ROE of 3.08%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Dr Lalchandani Labs Ltd generates profits from shareholders capital.
How is DLCL debt-to-equity ratio and what does it indicate?
DLCL has a debt-to-equity ratio of 0.45, which indicates moderate leverage that should be monitored.
What is DLCL dividend yield and is it a good dividend stock?
DLCL offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Dr Lalchandani Labs Ltd shares.
How has DLCL share price grown over the past 5 years?
DLCL has achieved 5-year growth rates of: Sales Growth -6.11%, Profit Growth -8.59%, and EPS Growth -8.59%.
What is the promoter holding in DLCL and why does it matter?
Promoters hold 31.15% of DLCL shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Dr Lalchandani Labs Ltd.
What is DLCL market capitalisation category?
DLCL has a market capitalisation of ₹9 crores, placing it in the Small-cap category.
How volatile is DLCL stock?
DLCL has a beta of N/A. A beta > 1 suggests the Dr Lalchandani Labs Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is DLCL operating profit margin trend?
DLCL has a 5-year average Operating Profit Margin (OPM) of 16.83%, indicating the company's operational efficiency.
How is DLCL quarterly performance?
Recent quarterly performance shows Dr Lalchandani Labs Ltd YoY Sales Growth of -3.76% and YoY Profit Growth of 33.33%.
What is the institutional holding pattern in DLCL?
DLCL has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Dr Lalchandani Labs Ltd stock.